Lilly announces a $5 billion Virginia manufacturing site

Eli Lilly said on September 16, 2025, that it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, just west of Richmond ^[1]. The company said the plant will be its first dedicated, fully integrated site for making active pharmaceutical ingredients and finished drug products for its "bioconjugate" platform and monoclonal antibody portfolio, technologies used mainly for cancer and autoimmune disease, not for its GLP-1 weight-loss or diabetes drugs ^[1][4].

The project is expected to create more than 650 permanent manufacturing jobs and about 1,800 construction jobs, and Lilly said it should be finished within five years ^[1]. It is the first of four new U.S. manufacturing sites the company plans to announce this year as part of a broader $27 billion pledge for domestic plants, which itself sits inside $50 billion in U.S. capital spending commitments Lilly has made since 2020 ^[1][2][4]. Lilly's investment and job figures for the Virginia site go beyond what it originally submitted for state incentives, and the company estimates every dollar spent there will generate up to four dollars in local economic activity ^[1].

CNBC reported that Lilly CEO David Ricks said the new capacity is meant to support the company's pipeline of future medicines, including antibody-drug conjugates that combine targeted antibodies with cancer-killing payloads, a type of drug Lilly does not currently have the domestic capacity to manufacture from start to finish ^[4]. Ricks said some production will shift to Virginia from other Lilly sites, mostly in Europe, and that the company chose the location for its logistics, workforce and readiness, since construction had already begun there for a different industrial use ^[4]. He also said the decision was driven more by U.S. tax policy than by the threat of pharmaceutical tariffs that President Trump has floated, though CNBC noted drugmakers broadly have been expanding U.S. production amid those tariff threats ^[4].

Why it matters for patients

This specific Virginia plant will not make Ozempic, Wegovy, Mounjaro, Zepbound or any other GLP-1 medicine; it is built for cancer and autoimmune drugs using bioconjugate and antibody technology ^[1][4]. People taking or considering semaglutide or tirzepatide products should not expect this announcement to directly change supply, price or availability of those specific drugs.

The broader significance is that Lilly continues to expand U.S. drug manufacturing overall, and CNBC noted the company's prior investments have already helped ease shortages of Zepbound and Mounjaro by adding production capacity across its network ^[4]. Whether this pattern of onshoring, partly a response to potential pharmaceutical tariffs and to U.S. tax incentives, eventually affects capacity, cost or supply of GLP-1 drugs specifically is not addressed in these sources and is not yet known.

What happens next

Lilly said it plans to announce its three remaining new U.S. manufacturing sites later this year, with all four expected to begin producing medicines within five years ^[1][2][4]. The Virginia facility itself is expected to be completed within that same five-year window ^[1]. Details on which therapies each of the other three sites will produce, and whether any will focus on GLP-1 manufacturing, are not yet available in the material reviewed here.